Everest Medicines (1952) Fireside chat summary

Introduction and agenda

• Renée Lucander introduced the discussion, briefly covering NEFECON, marketed as TARPEYO in the U.S. and Kinpeygo in Europe, before turning to the China market and regional plans.�

• The agenda covered the China IgA nephropathy market, NEFECON’s development and anticipated launch, commercial strategy, and audience questions.�

• U.S. net sales were $20.5 million at the end of Q3; launch activity included 730 enrollments and 480 prescribing nephrologists.�

Background and experience of the speaker

• Rogers Luo joined Everest Medicines as CEO about three months before the event, after 27 years in pharma and biotech and three years as a surgeon in a Shanghai public hospital.�

• His experience spans MSD, Novartis, Roche, Guidant, and Brii Biosciences, including work in China and at Novartis headquarters in Basel.�

• Luo cited launches of high-profile specialty and primary-care products in China; he described joining as the business moved from licensing toward commercial launches and integrated capabilities.�

Current industry trends

• China’s CKD prevalence was cited at 10.8%, or 120 million people; IgA nephropathy was estimated at 4–5 million patients, with 80,000–150,000 newly diagnosed biopsy-proven cases annually.�

• Glomerular disease accounts for over 50% of ESRD in China; IgA nephropathy is the most common primary glomerular disease, representing 35%–50% in cited studies.�

• China’s treatment pathway typically starts with RAS inhibitors; systemic steroids may follow if proteinuria remains high, while some patients avoid steroids because of side effects.�

• Luo described a shift from regional licensing toward in-house discovery, manufacturing, and commercialization; a $520 million Hong Kong IPO and $455 million TRODELVY rights divestment supported investment and reprioritization.�